Latest Period
Q2 2026
Security Snapshot
Akari Therapeutics Plc - Ordinary Shares (AKTX) Institutional Ownership
CUSIP: 00972G405
13F Institutional Holders and Ownership History from Q1 2026 to Q2 2026
Institutions Reporting
9
Shares (Excl. Options)
149,980
Price
$10.24
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares
- Symbol
- AKTX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 149,980
- Total 13F value
- $1,535,726
- Portfolio coverage rank
- 0%
- Share change
- +90,309
- Value change
- +$1,122,711
- Number of holders
- 9
- Shares outstanding
- 140,105,078,809
- SEC-reported price per share
- $8.46
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AKTX - Akari Therapeutics Plc - Ordinary Shares is tracked under CUSIP 00972G405.
- 9 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 6 to 9 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $307,305 to $1,535,726.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 9 institutions filings for Q2 2026.
Security key
00972G405
Latest holder period
Q2 2026
13F holders
9
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
AKTX full holder history
Akari Therapeutics Plc SEC filings
Akari Therapeutics Plc company facts
Akari Therapeutics Plc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00972G405:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
AKTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| MMCAP International Inc. SPC | 8% | $25,200,000,000 | 8,000,000,000 | MMCAP International Inc. SPC | 02 Jun 2026 | |||
| BANK OF MONTREAL /CAN/ | 5.7% | $107,200,000,000 | 8,000,000,000 | Bank of Montreal | 30 Jun 2026 | |||
| White Lion Capital LLC | 5% | $93,821,955,592 | 7,001,638,477 | White Lion Capital LLC | 07 Aug 2026 |
As of 30 Jun 2026, 9 institutional investors reported holding 149,980 shares of Akari Therapeutics Plc - Ordinary Shares (AKTX). This represents 0% of the company’s total 140,105,078,809 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
2
Latest
Q2 2026
Rows shown
1-2 of 2